培美曲塞和吉西他滨单药治疗老年患者晚期非小细胞肺癌疗效

Clinical research of pemetrexed single-agent and gemcitabine single-agent in treatment of elderly advanced non-small cell lung cancer

目的观察培美曲塞和吉西他滨单药治疗老年患者晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法连续收集老年晚期NSCLC患者55例,采用χ2检验比较培美曲塞单药化疗27例与吉西他滨单药化疗28例的疗效及不良反应差异。结果培美曲塞组部分缓解(PR)4例、疾病稳定(SD)12例、疾病进展(PD)11例,控制率为59.3%,无疾病进展期(PFS)为5.9个月;吉西他滨组PR 3例、SD 11例、PD 14例,控制率为50.0%,PFS为5.1个月,两组比较差异无统计学意义(P>0.05);培美曲塞组血小板减少发生率为11.1%(3/27),吉西他滨组血小板减少发生率为21.4%(6/28),两组比较,差异有统计学意义(P<0.05)。结论培美曲塞与吉西他滨单药一线治疗老年晚期NSCLC疗效相似,但培美曲塞不良反应少,安全性更高。

Objective To evaluate the efficacy and safety of pemetrexed and gemcitabine single-agent first-line chemotherapy in the treatment of elderly advanced non-small cell lung cancer. Methods Fifty-five elderly patients with advanced NSCLC were collected,and theχ2 was performed between 27 cases with pemetrexed and 28 cases with gemcitabine in order to compare the differences in curative effect and adverse reaction. Results In group of pemetrexed,PR was in 4 cases,SD 12 cases,PD 11 cases,and the control rate was 59. 3%;PFS was 5. 9 months. In group of gemcitabine,PR was in 3 cases,SD 11 cases,PD 12 cases,and the control rate was 50. 0%;PFS was 5. 1 months. The difference between the two groups had no statistical significance(P>0. 05). Incidence rate of platelet reduction in pemetrexed group was 11. 1%(3/27),while that in gemcitabine group was 21. 4%(6/28),and there were statistical significances between them(P<0. 05). Conclusion The curative effect of pemetrexed and gemcitabine in single-agent first-line treatment of elderly advanced NSCLC is similar,but pemetrexed has less adverse reactions and thus higher security.